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Context: The Treatment for Adolescents With Depres-
sion Study evaluated fluoxetine (FLX), cognitive behav-
ioral therapy (CBT), and FLX/CBT combination (COMB)
vs pill placebo in 439 adolescents with major depressive
disorder. Treatment consisted of 3 stages: (1) acute (12
weeks), (2) continuation (6 weeks), and (3) maintenance
(18 weeks).
Objective: To examine rates of achieving and main-
taining sustained response during continuation andmain-
tenance treatments.
Design: Randomized controlled trial. Response was de-
termined by blinded independent evaluators.
Setting: Thirteen US sites.
Patients:Two hundred forty-two FLX, CBT, andCOMB
patients in their assigned treatment at the end of stage 1.
Interventions: Stage 2 treatment varied based on stage
1 response. Stage 3 consisted of 3 CBT and/or pharma-
cotherapy sessions and, if applicable, continued
medication.
Main OutcomeMeasures: Sustained response was de-
fined as 2 consecutive Clinical Global Impression–
Improvement ratings of 1 or 2 (“full response”). Patients
achieving sustained response were classified on subse-
quent nonresponse status.
Results: Among 95 patients (39.3%) who had not
achieved sustained response by week 12 (29.1% COMB,
32.5% FLX, and 57.9% CBT), sustained response rates
during stages 2 and 3 were 80.0% COMB, 61.5% FLX,
and 77.3% CBT (difference not significant). Among the
remaining 147 patients (60.7%) who achieved sus-
tained response byweek12,CBTpatientsweremore likely
than FLXpatients tomaintain sustained response through
week 36 (96.9% vs 74.1%; P=.007; 88.5% of COMB pa-
tients maintained sustained response through week 36).
Total rates of sustained response by week 36 were 88.4%
COMB, 82.5% FLX, and 75.0% CBT.
Conclusions:Most adolescents with depressionwho had
not achieved sustained response during acute treatment
did achieve that level of improvement during continua-
tion andmaintenance therapies. The possibility that CBT
may help the subset of adolescents with depression who
achieve early sustained response maintain their re-
sponse warrants further investigation.
Trial Registration: clinicaltrials.gov Identifier:
NCT00006286.
Arch Gen Psychiatry. 2008;65(4):447-455
G IVEN THE HIGH PROBABIL-ity of relapse and recur-rence following favor-able response to treatmentin adults and adolescents
with depression,1,2 guidelines have beende-
veloped to extend beyond acute treat-
ment. The goal of continuation treatment
is toprevent relapse following remission (ie,
the initial period during which the person
has responded to treatment3), whereas the
goal of maintenance treatment is to pre-
vent recurrence following recovery (ie, once
the person has been symptom-free long
enough toconsider the initial depressiveepi-
sode over). Little is known concerning ef-
fective continuationandmaintenance thera-
pies for adolescents with depression, and
practice guidelines for adolescents4,5 have
been adopted from the larger bodyof guide-
lines for long-term treatment of adultswith
depression.6-9
Previous postacute treatment research
with adolescents with depression is ex-
tremely limited. A 6-month course of cog-
nitive behavioral therapy (CBT) continu-
ation treatment in 17 patients (aged 11-17
years) following acute CBT10 was superior
tono treatment in ahistorical control group
of 12 patients, and fluoxetine (FLX) con-
tinuation treatmentwas superior to pill pla-
cebo (PBO) in reducing depression re-
Author Affiliations are listed at
the end of this article.
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lapse among 40 patients (aged 8-18 years) who had
responded to FLX acute treatment.11 In the former study,
the cumulative relapse risk was 20% among continuation
CBT patients vs 50% among historical controls. In the lat-
ter study, relapse, which was defined as either a Chil-
dren’s Depression Rating Scale–Revised12 (CDRS-R) score
higher than 40 or physician opinion over a 32-week post-
acute phase, occurred in 34% of patients who continued
taking FLX vs 60% of those switched to PBO.
In the only study to our knowledge that evaluated a
maintenance treatment for adolescent depression, Clarke
and colleagues13 examined the degree to which an indi-
vidual CBT booster intervention reduced depression re-
currence. After an 8-week, 16-session group CBT inter-
vention, one-third of the 54 adolescents (aged 14-18 years)
who completed treatment (regardless of response sta-
tus) were randomly assigned to individual boosters ev-
ery 4 months over a 2-year follow-up. The booster con-
ditionwas not associatedwith less depression recurrence
among recovered patients (27% recurrence amongbooster
patients vs 8% among assessment-only controls, results
not significant) but did significantly improve the rate of
recovery for adolescents who still had depression fol-
lowing acute treatment (100% recovery among booster
patients vs 50%among assessment-only controls;P .05).
This study suggests that an important function of post-
acute treatments may be to facilitate continued improve-
ment among partial responders.
The goal of the present study was to examine the rates
of sustained improvement during continuation andmain-
tenance therapies in the Treatment for AdolescentsWith
Depression Study14-16 (TADS). TADS is a randomized con-
trolled trial that evaluated the effectiveness of 3 treat-
ments for adolescents with major depressive disorder
(MDD), FLX pharmacotherapy with clinical manage-
ment, CBT, and the combination of FLX and CBT
(COMB), relative to clinicalmanagementwith PBO.TADS
treatment was provided in 3 stages: (1) acute treatment
lasting 12 weeks, (2) continuation treatment lasting 6
weeks and varying in intensity based on the patient’s re-
sponse to acute treatment, and (3) maintenance treat-
ment lasting 18 weeks, in which patients met with their
clinician(s) 3 times and, if applicable, continued taking
medication. Previous publications reported that theCOMB
and FLX conditions had higher response rates than CBT
or PBOduring stage 1,14 andCOMBperformed better dur-
ing stages 2 and 3 than either of themonotherapies, which
had very similar response rates.17
Our outcome measure in the present study was sus-
tained response, which is defined as 2 consecutive rat-
ings of a full response in assessments conducted 6 weeks
apart. TADS follow-up did not include the collection of
weekly symptom ratings necessary to determine recov-
ery and recurrence.3,18 Our creation of the sustained re-
sponse variable provides an alternative outcome that an-
swers important questions in clinical decisionmaking that
must be answered before a patient is considered recov-
ered (eg, Is my patient responding to this treatment? Is
this apparent response more than transitory? Should I
augment treatment or change modalities?). Although it
was not an original aim of TADS, data during TADS con-
tinuation and maintenance therapies provided a unique
and valuable opportunity to address 2 issues: (1) Towhat
degree do patients who have not achieved sustained re-
sponse during acute therapy subsequently achieve sus-
tained response during continuation and maintenance
therapies? (2) Among patients who achieved sustained
response during acute therapy, howmanymaintain their
sustained response through continuation and mainte-
nance therapies? The present study extends the previ-
ous stage 3 TADS publication17 by requiring a main-
tained response rather than the one-time achievement of
a positive response and by examining the degree towhich
sustained response is maintained once achieved. In ad-
dition, although data on treatment adherence and com-
pliance following acute treatment were not available, we
examine, as a secondary aim, whether treatment modali-
ties differed in rates of attendance, which serves as one
basic indicator of treatment use. Retaining the patient is
a basic gauge of the perceived value of postacute care. In
addition, differences in the rates of sustained response
may be influenced by condition differences in atten-
dance. One possible explanation for the nonsignificant
recurrence prevention finding of the booster protocol in
Clarke et al13 was that many adolescents assigned to
booster therapy (perhaps more than half) failed to at-
tend postacute treatment. Although we are unable to
evaluate the degree to which patients compliedwith con-
tinuation and maintenance therapies in TADS, we com-
pared whether treatment attendance varied across
conditions.
METHODS
The TADS design has been extensively documented in previ-
ous publications14-16 and will be only briefly reviewed herein.
STAGE 1 PARTICIPANTS AND PROCEDURES
Between 2000 and 2003, 439 adolescents at 13 sites were en-
rolled. Both adolescents and parents provided written in-
formed assent/consent. Institutional review boards at each site
approved and monitored the protocol. Diagnoses of MDD and
associated comorbidities at baseline were established using the
Schedule for Affective Disorders and Schizophrenia for School-
Age Children–Present and Lifetime Version.19 TADS used 2 pri-
mary measures of depression status assessed at baseline and
weeks 6, 12, 18, 24, and 36 by an independent evaluator blind
to condition: (1) the 17-item CDRS-R11 as a continuous mea-
sure of depression severity in the past week, and (2) re-
sponder status on the 7-point Clinical Global Impression–
Improvement (CGI-I).20
Inclusion criteria were (1) 12 to 17 years of age, (2) diag-
nosis of current DSM-IV MDD, (3) CDRS-R total score of 45
or higher, (4) stable mood symptoms for at least 6 weeks, and
(5) impairment in at least 2 settings. Exclusion criteria in-
cluded (1) psychiatric disorders requiring out-of-protocol treat-
ments, (2) 1 failed CBT trial or 2 failed selective serotonin re-
uptake inhibitor trials for depression, (3) current psychiatric
treatment (other than stable dose of stimulant medication for
attention-deficit/hyperactivity disorder), (4) non-English speak-
ing, (5) confounding medical condition, (6) previous intoler-
ance to FLX, (7) pregnant or sexually active while refusing ac-
ceptable birth control, or (8) danger to self or others.
Eligible participants were randomly assigned to FLX, CBT,
COMB, or PBO using stratified randomization at the coordi-
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nating center. Patients and staff remained masked in the “pills
only” conditions (FLX and PBO) until week 12, at which time
patients and clinicians were unblinded. At the end of stage 1,
PBO nonresponders were provided with the TADS treatment
of their choice, and nonresponders to active treatment (6 in
COMB, 11 in FLX, 11 in CBT) were withdrawn from treat-
ment and provided with referrals for alternative care.
Given our focus on stages 2 and 3 in the present study, pa-
tients initially assigned to PBOwere not included. Rates of par-
ticipation at each project stage are shown in the CONSORT
(Consolidated Standards of Reporting Trials) diagram (Figure).
A total of 327 adolescents were randomized to an active treat-
ment; 270 completed the study through week 12. The present
sample (n=242) consisted of observed cases (ie, adolescents
in their randomized treatment armwith no treatment augmen-
tation) at the start of stage 2. The sample had a mean (SD) age
at intake of 14.6 (1.5) years and included 140 female adoles-
cents (57.9%). One hundred ninety participants (78.5%) clas-
sified their race/ethnicity status as white; 21 (8.7%), African
American; 17 (7.0%), Hispanic white; 4 (1.7%), Hispanic black;
3 (1.2%), Asian; and 7 (2.9%), other. Participants in the present
study were compared on demographic factors (age, sex, race/
ethnicity, income) and depression severity (CDRS-R and Clini-
cal Global Impression–Severity [CGI-S] scores) with the 85 pa-
tients assigned to active treatment who had been excluded.
Differences were nonsignificant, with one exception: retained
2804 Patients screened by telephone
1088 Assessed by diagnostic interview 
549 Completed baseline assessments
439 Eligible for randomization
92 OC
107 COMB
15 DC
86 OC
6 DC
5 DC
13 DC
78 N
81 OC
75 N
68 OC
109 FLX
91 OC
18 DC
80 OC
11 DC
15 DC
10 DC
66 N
65 OC
64 N
55 OC
111 CBT
87 OC
24 DC
76 OC
11 DC
6 DC
15 DC
66 N
70 OC
63 N
55 OC
327 Total
270 OC
57 DC
242 OC
28 DC
26 DC
38 DC
210 N
216 OC
202 N
178 OC
Randomization
Week 12
Discontinuation
of randomized treatment
because of nonresponse
(as per protocol)
Start of stage 2
Week 18
Week 36
Stage 1
Stage 2
Stage 3
Figure. Treatment for Adolescents With Depression Study flow diagram for the 242 patients who continued randomized treatment after 12 weeks of acute
treatment. Reasons for discontinuation prior to randomization have been previously reported.15(p811) The 242 youths who started stage 2 as an observed case (OC)
were evaluated in the current analysis. All 112 patients assigned to the placebo condition discontinued randomized treatment at the end of stage 1 as per protocol
and are excluded from the current analysis. COMB indicates combination of fluoxetine (FLX) and cognitive behavioral therapy (CBT); DC, discontinuation of
randomized treatment because of premature termination, nonresponse at the end of stage 1, or study exit; N, number of Clinical Global Impression–
Improvement20 assessments completed for 242 cases at weeks 18 and 36.
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patients consisted of a higher proportion of white adolescents
(78.5% vs 62.1%; P=.002). Data were available for 210 partici-
pants (86.8%) at the end of stage 2 and 202 (83.5%) at the end
of stage 3.
INTERVENTIONS
Medication
Stage 1medicationmanagement includedmonitoring status and
medication effects during 20- to 30-minute visits. Doses be-
gan at 10 mg/d, titrated as necessary, up to 40 mg/d by week 8.
At the week 12 visit, the dose was raised to 50 or 60 mg/d in
patients rated by the clinician as partial responders (ie, CGI-I
score=3). Full responders at the end of stage 1 (CGI-I score=1
or 2 by clinician rating) weremaintained at the same FLX dose.
In stage 2, full responders had 2 office visits; partial respond-
ers had 4 office visits. In stage 3, patients were followed up ev-
ery 6 weeks with a 20- to 30-minute medication visit. Other
than reductions because of major adverse effects, medication
dose did not change without special approval from the confer-
ence call peer supervision group.
Cognitive Behavioral Therapy
TADS CBT in stage 1 included 15 sessions (a combination of
adolescent only, parent psychoeducation, and conjoint). Pa-
tients rated by their clinician as partial responders at the end
of stage 1 received 6 additional weeks of weekly CBT in stage
2, whereas stage 1 full responders shifted to biweekly CBT ses-
sions. During stage 3, patients met with their therapist every 6
weeks for 3 CBT booster sessions.
Combination Treatment
Combination treatment consisted of all components from the
medication management and CBT protocols.
DEFINITIONS OF DEPRESSION STATUS
Treatment Response
Treatment response status, relative to baseline, was deter-
mined at each assessment based on independent evaluatorCGI-I
scores.When a week 12 independent evaluator score wasmiss-
ing, last observation carried forward procedures were imple-
mented. Adolescents with CGI-I scores of 1 (“very much im-
proved”) or 2 (“much improved”) were considered full
responders, those with a CGI-I score of 3 (“minimally im-
proved”) were considered partial responders, and those with a
CGI-I score of 4 (“no change”) and higher (indicating wors-
ening) were considered nonresponders. Thirty-one adoles-
cents rated by the independent evaluator as week 12 nonre-
sponders were included in the present study because the patient
had been rated by the clinician(s) as either a partial or full re-
sponder and had remained in his or her treatment arm with-
out treatment augmentation. CGI-I ratings were made by the
independent evaluator after the CDRS-R and scores between
the 2 measures were highly correlated (ie, Spearman correla-
tions between CGI-I and CDRS-R scores at weeks 12, 18, and
36 were r=0.81, 0.80, and 0.73, respectively; all P .001).
Sustained Response Status
Sustained response status was based on the maintenance of in-
dependent evaluator CGI-I scores. The following 2 assump-
tions were applied when response status data weremissing: (1)
adolescents missing week 6 data were assumed to be nonre-
sponders at week 6, and (2) when 1 or more consecutive as-
sessments were missing, and response scores before and after
themissing assessment(s) were identical, we assumed the same
response status for the missed assessments.
Patients were categorized into 1 of 3 sustained response
groups at each assessment. Sustained response was defined as
2 consecutive ratings of “full responder.” Possible sustained re-
sponse was defined as 1 rating of “full responder” followed by
no additional stage 2 or 3 data. All other response patterns were
defined as nonsustained response. At week 12, only 4 patients
(1 COMB, 1 FLX, 2 CBT) were classified as possible sustained
response. For ease of presentation, they were combined with
the nonsustained response group at week 12.
Maintenance of Sustained Response
Once patients experienced sustained response, sustained re-
sponse status at subsequent assessments was classified as (1)
“failed to maintain,” given a subsequent assessment of nonre-
sponder or partial responder (CGI-I score=3-7); (2) “main-
tained sustained response,” given continued assessments of full
responder; or (3) “unknown,” if additional independent evalu-
ator data following sustained response were not available.
STATISTICAL METHODS
Analyses were conducted by 2 of us (S.G.S. and S.T.T.). Fisher
exact tests were conducted to test for between-treatment dif-
ferences in rates. The level of significance was set at .05 for each
2-tailed statistical test.
Differences in the amount ofmissing data between the 3 con-
ditions could have affected our ability to detect treatment ef-
fects. Differences in the amount of missing independent evalu-
ator data across conditions and assessmentswere nonsignificant,
with one exception: week 24, P .01. Paired contrasts indi-
cated more missing data for FLX compared with COMB pa-
tients (22.5% vs 5.8%; P .01); CBT patients were intermedi-
ate (13.2% missing data) and did not differ from the other 2
groups. Given the lack of systematic differences across condi-
tions in missing data, no adjustments were made.
RESULTS
SUSTAINED RESPONSE IN STAGE 1
Among the 242 participants, 147 (60.7%) were classi-
fied as having a sustained response by week 12: 70.9%
COMB, 67.5% FLX, and 42.1% CBT. The overall differ-
ence was significant: n=147; 22=16.35; P .001. Paired
contrasts indicated that, comparedwithCBT, rates of sus-
tained response by week 12 were significantly higher for
COMB (P .001) andFLX (P=.001) patients, whose rates
did not differ.
SUSTAINED RESPONSE IN STAGES 2 AND 3
FOR PATIENTS WHO HAD NOT ACHIEVED
SUSTAINED RESPONSE IN ACUTE TREATMENT
Ninety-five of the 242 participants (39.3%) were classi-
fied as having a nonsustained response byweek 12: 29.1%
COMB, 32.5% FLX, and 57.9% CBT. Table 1 shows
whether sustained response during weeks 18 and 36 was
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achieved for these patients as a function of condition. The
majority of adolescents who had not achieved sustained
response by week 12 achieved either definite or pos-
sible sustained response byweek 36: 80.0%COMB, 61.5%
FLX, and 77.3% CBT. Sustained response rates by week
18 are not presented in Table 1 but indicated that treat-
ment response tended to occur slowly (48.0% COMB,
34.6% FLX, and 31.8% CBT). Differences in sustained
response status across the 3 treatment conditions at both
weeks 18 and 36 were nonsignificant.
MAINTENANCE OF SUSTAINED RESPONSE IN
STAGES 2 AND 3 FOR PATIENTS WHO ACHIEVED
SUSTAINED RESPONSE IN ACUTE TREATMENT
Thenext analyses examinedwhether the 147 patientswho
achieved sustained response by week 12maintained that
status during TADS continuation and maintenance
therapy. The maintenance of sustained response during
weeks 18 and 36 for week 12 sustained responders is
shown in Table 2. Among this subset of patients who
responded well to acute therapy, the majority (82.3%)
maintained their sustained response throughout stages
2 and 3 (ie, assessments at weeks 18, 24, 30, and 36).
Fifteen percent, however, failed to maintain their sus-
tained response, with rates differing as a function of treat-
mentmodality: 11.5%COMB, 25.9%FLX, and 3.1%CBT.
The overall treatment by sustained response status effect
was significant (Fisher exact P=.01). Paired contrasts in-
dicated that the maintenance of sustained response was
higher for CBT compared with FLX (P=.007) and ap-
proached significance in COMB compared with FLX
(P= .06). Rates of maintaining sustained response in
COMB vs CBT did not differ.
Table 1. Sustained Response During Weeks 18 Through 36 for Patients Who Had Not Achieved Sustained Response by Week 12
Treatment Arm
No. (%) of Patients Who Had Not Achieved
Sustained Response by Week 12
Weeks 18 and 36
Sustained Response Statusa No. (%)
COMB (n=86) 25 (29.1) Sustained response 15 (60.0)
Possible sustained response 5 (20.0)
Nonsustained response 5 (20.0)
FLX (n=80) 26 (32.5) Sustained response 12 (46.2)
Possible sustained response 4 (15.4)
Nonsustained response 10 (38.5)
CBT (n=76) 44 (57.9) Sustained response 25 (56.8)
Possible sustained response 9 (20.5)
Nonsustained response 10 (22.7)
All Active Treatments (n=242) 95 (39.3) Sustained response 52 (54.7)
Possible sustained response 18 (18.9)
Nonsustained response 25 (26.3)
Abbreviations: CBT, cognitive behavioral therapy; COMB, FLX/CBT combination; FLX, fluoxetine.
aThe “Weeks 18 and 36 Sustained Response Status” column indicates whether the patient achieved sustained response at any point during the period. If the
patient had multiple response classifications across the period, the best response status was counted. The clinical ordering of response status from best to worse
is “sustained response” (ie, 2 consecutive ratings of “full responder,” defined as a Clinical Global Impression–Improvement20 score=1 or 2), “possible sustained
response” (ie, 1 rating of “full responder” either at the end of stage 3 or followed by missing assessments only), and “nonsustained response” (all other responder
patterns).
Table 2. Maintenance of Sustained Response During Weeks 18 Through 36 for Patients Who Achieved Sustained Response by Week 12a
Treatment Arm
No. (%) of Patients Experiencing
Sustained Response by Week 12
Weeks 18 and 36
Maintenance Status No. (%)
COMB (n=86) 61 (70.9) Failed to maintain 7 (11.5)
Maintained sustained response 53 (86.9)
Unknown 1 (1.6)
FLX (n=80) 54 (67.5) Failed to maintain 14 (25.9)
Maintained sustained response 38 (70.4)
Unknown 2 (3.7)
CBT (n=76) 32 (42.1) Failed to maintain 1 (3.1)
Maintained sustained response 30 (93.8)
Unknown 1 (3.1)
All Active Treatments (n=242) 147 (60.7) Failed to maintain 22 (15.0)
Maintained sustained response 121 (82.3)
Unknown 4 (2.7)
Abbreviations: See Table 1.
aPatients who experienced sustained response were classified on the degree to which they maintained their sustained response status for subsequent
assessments. Maintenance status consisted of “failed to maintain” (ie, a subsequent assessment of “nonresponder” or “partial responder”; Clinical Global
Impression–Improvement20 score=1-3), “maintained sustained response” (ie, continued assessments of “full responder”), or “unknown” (ie, no assessment data
were available following sustained response).
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POTENTIAL DIFFERENCES IN DEPRESSIVE
SEVERITY ASSOCIATED WITH SUSTAINED
RESPONSE FOR DIFFERENT
TREATMENT CONDITIONS
Given that a smaller proportion of CBT patients
reached sustained response during stage 1 compared
with COMB and FLX patients (42% vs 71% and 68%,
respectively), it was possible that this subset of CBT
patients had been less depressed at baseline than
COMB and FLX patients who achieved sustained
response during stage 1. CDRS-R scores at baseline for
the COMB, FLX, and CBT patients who achieved sus-
tained response by week 12 were compared and did
not differ (baseline mean [SD] scores=60.4 [12.2],
59.2 [10.4], and 57.5 [7.9], respectively). Overall gen-
eral linear model results were F2,144=0.77; P=.46. As a
secondary check, we compared the 3 groups of sus-
tained responders on depression level at week 12.
Differences between COMB, FLX, and CBT groups
were nonsignificant (week 12 mean [SD] CDRS-R
scores=28.3 [7.7], 29.7 [6.2], and 29.6 [6.5], respec-
tively). Overall general linear model results were
F2,141=0.67; P=.51. Previously, Curry and colleagues21
identified 3 moderators of treatment condition, annual
family income, severity of depression (CGI-S score),
and cognitive distortions (Children’s Negative Cogni-
tive Errors Questionnaire22 score), and we compared
sustained responders in the 3 conditions on baseline
levels of these 3 moderators. Differences on family
income and depression severity as per CGI-S score
were nonsignificant, although group differences on
cognitive distortions were present (F2,144 = 3.92;
P= .22), with higher cognitive distortions for COMB
compared with FLX patients (mean [SD] scores=68.3
[19.3] vs 58.8 [19.0]; P= .008; CBT patients did not
differ from either group, mean [SD] score = 60.8
[17.3]).
TREATMENT ATTENDANCE
IN STAGES 2 AND 3
Condition differences in the rates of maintaining sus-
tained response may have been influenced by differen-
tial attendance. Because stage 2 treatment was designed
to provide more treatment for partial responders com-
pared with full responders, attendance was examined as
a function of stage 1 response. Using the Wilcoxon rank
sum test, all differences in attendance during stages 2
and 3 between conditions were nonsignificant. Full
responders at week 12 (n=161) attended a mean (SD)
4.3 (2.0) of the 5 pharmacotherapy sessions and 4.9
(2.3) of the 6 CBT sessions. Week 12 partial responders
(n=50) attended 4.3 (2.6) of the 6 pharmacotherapy
sessions and 6.0 (2.2) of the 9 CBT sessions.
Treatment provided outside of TADS was infrequent
(6.2% began taking non-TADS antidepressants; 12.0%
began non-TADS psychotherapy during stages 2 and 3).
Analyses examining the achievement and maintenance
of sustained response were recomputed after deselect-
ing the 34 patients who received adjunctive treatment
and the pattern of results remained identical.
COMMENT
The purpose of this study was to describe the rates at
which adolescents with depression in 3 treatment arms
were able to achieve and maintain a sustained response
during continuation and maintenance therapy as devel-
oped in TADS. Information on sustained response can
be used by the clinician and the family to guide impor-
tant decisions regarding the optimal course of treat-
ment after the acute phase.
Rates of sustained response during acute therapy
were significantly higher for the 2 conditions that
included FLX compared with CBT monotherapy.
Regarding the achievement of sustained response dur-
ing continuation and maintenance therapies, 55% of
adolescents with depression who had not reached sus-
tained response by the end of acute treatment subse-
quently achieved this outcome during additional
therapy, with an additional 19% possibly reaching this
threshold. By the end of maintenance therapy, rates of
sustained response across the 3 conditions were compa-
rable, suggesting that CBT has a slower effect in treating
depression. The findings suggest that approximately
three-quarters of adolescents with depression who have
not fully responded after 12 weeks of acute treatment
will experience sustained response with further treat-
ment. As noted earlier, Clarke and colleagues13 found
that additional treatment produced further symptom
reduction in those who were partially recovered during
acute treatment. Also consistent with the present find-
ings, from a study of 107 adolescents treated with vari-
ous psychosocial interventions,23 among the subset of
18 patients who had subsyndromal depression (ie, 2-3
MDD symptoms) at the end of acute treatment, 94%
experienced recovery in the 2-year follow-up period,
which included 2 to 4 booster sessions for all patients
and open treatment for approximately half. In conclu-
sion, these findings emphasize the value of ongoing
treatment in facilitating the depression recovery pro-
cess, even if psychosocial treatment occurs on a signifi-
cantly less frequent basis. The findings also suggest that
continuation and maintenance treatment guidelines
explicitly recognize the value of “continued response
among partial responders” as a stated goal.
The second method of evaluating continuation and
maintenance therapies consisted of the degree to which
patients who achieved sustained response during acute
treatment were able to maintain that response through
continuation and maintenance therapies. To our knowl-
edge, TADS is the first study to contrast the impact of
psychosocial and pharmacotherapy treatments on
depression response in adolescents. Although the rate
of sustained response improvement during acute treat-
ment for patients receiving CBT was significantly lower
than combination therapy or FLX monotherapy, among
the subset of CBT patients who did achieve this mea-
sure of improvement by week 12, only 3.1% failed to
maintain their sustained response during the following
24 weeks. This rate was significantly lower than that of
patients receiving FLX (25.9%), a rate similar to the
relapse rate of 34% over 32 weeks of continued FLX
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management reported by Emslie et al.11 This difference
is the first TADS finding in which CBT monotherapy
significantly outperformed the FLX monotherapy con-
dition, although it only applied to the subset of patients
still in their assigned treatment arm. The sustaining of
response, which is consistent with findings from some
adult studies,24 is promising and warrants further
investigation.
Although patients were assigned randomly to treat-
ment modalities, the rate and degree to which patients
across conditions achieved sustained response in acute
therapy may have unbalanced the groups with respect
to preexisting characteristics, a phenomenon that has
been referred to as the “differential sieve effect.”25 Thus,
while one interpretation of the present findings is that
CBT improves the ability of adolescents with depression
who respond to maintain their positive response to
treatment, it is also possible that these results were due
to other factors, such as patients who are at risk for
relapse and recurrence being more likely to respond to
pharmacotherapy compared with CBT. We examined 4
factors that might bias the results (ie, 2 measures of
depression severity, family income, and cognitive dis-
tortions). We found no evidence suggesting that the
group of CBT patients who achieved sustained response
during stage 1 entered treatment less severely depressed
than sustained responders in either the COMB or FLX
conditions or differed on other variables previously
found to moderate TADS treatment.21 Nonetheless, sus-
tained responders across conditions could have differed
on a number of other pretreatment factors and the phe-
nomenon of a differential sieve effect needs to be care-
fully examined in future research.
Although quite limited, previous research with ado-
lescents with depression has failed to detect a protective
effect for CBT. For example, among 54 child/adolescent
patients treated with either CBT or an expanded assess-
ment procedure who were followed up for 2 years, 20%
experienced recurrence with no differential treatment ef-
fects,26 although patients received only 6 sessions of CBT
on average. As noted earlier, Clarke et al13 found no effect
for CBT booster sessions in the prevention of depres-
sion recurrence. In a follow-up study of the 3 psychoso-
cial interventions evaluated by Birmaher and col-
leagues,27 treatment conditions did not predict recurrence.
Conversely, in the studywith adults with depression that
most closely parallels theTADSdesign,Hollon et al28 com-
pared relapse/recurrence rates for adult patients who re-
mitted during cognitive therapy with patients who re-
mittedwhile taking antidepressantmedication and found
that cognitive therapy continuation treatment at a greatly
reduced dose (3 booster sessions over a 12-month pe-
riod) was as effective as continued full-dosage pharma-
cotherapy in preventing relapse.
We also examined attendance rates in continuation
and maintenance therapy as a basic aspect of treatment
use. Both full and partial responders by week 12 ap-
peared to find value in both continuation and mainte-
nance treatments as designed by TADS and there was no
indication that rates of sustained response were differ-
entially impacted across treatments by attendance. In ad-
dition, attendance rates were comparable for patients as-
signed to combination therapy relative to either
monotherapy, suggesting that patients engaged in 2 forms
of treatment did not reduce their commitment to either
monotherapy.
Several important limitations to the present study need
to be acknowledged. First, our outcomemeasure of sus-
tained response is related to, but not synonymous with,
the criteria of recovery or recurrence.While the achieve-
ment of sustained response represents a significant re-
duction in depression severity, a subset of these adoles-
cents were still experiencing persisting depressive
symptoms or some degree of functional impairment. The
TADS assessment battery did not track the week-by-
week course of depression symptoms necessary to diag-
nose depression recovery, relapse, or recurrence with ab-
solute confidence. Thus, comparison of the present
findingswith previous research is somewhat limited. Sec-
ond, we had no PBO or untreated group following acute
treatment. This design decision was made purposefully,
for both scientific and ethical reasons, but it meant that
we do not know howmany patients would have achieved
and maintained a sustained response with no postacute
intervention. That said, given the lower rates of sus-
tained response among CBT patients at the end of acute
treatment and the higher rates of failure to maintain sus-
tained response for patients receiving FLX mono-
therapy, the present findings clearly support the value
of continuation andmaintenance therapies. A third, and
very important, limitation of the present study is the lack
of data on treatment compliance or adherence for either
CBT or pharmacotherapy in the continuation andmain-
tenance phases of TADS. It is possible that adolescents
receiving FLX discontinued or were more erratic with
medication following the positive response, as the dis-
continuation of antidepressant therapy among adults is
frequent.29We recognized that treatment attendance serves
as a necessary but not sufficient factor in CBT and is not
even required for adequate pharmacotherapy, if the pa-
tients continue to take their medication. A fourth limi-
tation is that a small subset of TADS participants (n=28
[10%]) had been evaluated by the treatment provider to
be clear nonresponders at the end of stage 1 acute treat-
ment and were referred for treatment outside of TADS
prior to stage 2. Thus, the present findings may be gen-
eralized to patients who have demonstrated at least a par-
tial response to medications or CBT within 12 weeks.
Lastly, some attrition had occurred during stage 1, which
may have influenced the present findings. Although not
significant across conditions, approximately 17%of TADS
patients discontinued or augmented treatment during
stage 1.
Given that a larger proportion of patients recover
from FLX therapy than CBT but the sustained response
may not be as enduring, one hypothesis for future
research is that FLX monotherapy needs to be aug-
mented once depression recovery has occurred, and
CBT would seem to be a reasonable place to start. Con-
tinuation and maintenance treatments in TADS were
designed to extend the acute treatment modality rather
than to introduce new treatment modalities. While the
issue of a stepped program of care has not, to our
knowledge, been evaluated in adolescents with depres-
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sion, there has been a recent shift toward the use of
sequencing treatments to achieve remission in adults, as
in the landmark study Sequenced Treatment Alterna-
tives to Relieve Depression.30 Stepped care protocols are
based on the rationale of limiting the use of more
expensive and time-consuming treatments, such as
combination treatment, to the patients with more
severe depression or treatment-resistant patients.
Although much of the literature describes the sequenc-
ing of medication strategies, there is some support for
the sequencing of pharmacotherapy and psychosocial
treatments.31,32
Another direction for future research consists of the
adolescent’s depressive course once treatment has ended.
Adult patients who received cognitive therapy, with or
without continuing clinicalmanagement, have been found
to have significantly lower relapse and recurrence rates
than medication patients, following withdrawal from
medication.33-35 The rates ofMDD recurrence in the 1-year
open follow-up (stage 4) of TADS will be addressed in a
subsequent report.
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